Optimizing Dose of Bupivacaine in Combined Spinal Epidurals To Reduce Side Effects

NCT ID: NCT02159807

Last Updated: 2019-01-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

170 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-24

Study Completion Date

2017-12-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine what dose of medication administered through a combined spinal epidural (CSE) provides the optimal pain relief with the minimal amount of side effects. The 3 doses studied here (1.25, 1.66 and 2.5mg) are routinely use on the labor floor (depending on the physician preference) but the idea is to quantify safety, efficacy and side effects for each of these doses.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A combined spinal epidural (CSE), which is the investigators' customary method of providing pain relief during your labor, is the identification of the epidural space in your lower back with a needle, followed by passing a thinner and longer needle through the first needle. This second needle will enter the patient's "spinal" (intrathecal) space by passing through the dura (thin covering separating the epidural space from the spinal space). The spinal (intrathecal) space is identified by flow of spinal fluid. The dura is the envelope around the spinal cord and the intrathecal space which is filled with spinal fluid. Medication will be injected at once into the spinal space, the thinner needle removed and a fine tube (catheter) will be threaded through the first needle into the epidural space. This catheter is in the epidural space and medication can be given through this catheter later on (hence the term combined) if needed. This study is a comparison of three different dosages (1.25mg, 1.66mg and 2.5 mg) of the local anesthetic (Bupivacaine) that we frequently use in the spinal, mixed with 20 mcg of Fentanyl (also routinely used in standard of care practice), and of its effects on the patient's blood pressure (risk of maternal's drop of the blood pressure with possible bad effects on the blood flow to the baby), on the patient's baby's heart rate (risk of slowing down of the baby heart rate as a consequence of decreased blood flow to the baby), and the patient's pain relief (higher dose of medications are usually more effective for maternal pain relief but have side effects that can be bad for the mother and the baby). The doses of Bupivacaine the investigator routinely use on the labor and delivery floor go from 1.25 to 2.5 mg depending on clinician preferences. These doses are considered standard of care in the literature.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1.25 mg Bupivacaine

1.25mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic

Group Type ACTIVE_COMPARATOR

Bupivacaine

Intervention Type DRUG

The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.

Fentanyl

Intervention Type DRUG

20 micrograms routinely administered in combination in the spinal anesthetic

1.66 mg Bupivacaine

1.66mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic

Group Type ACTIVE_COMPARATOR

Bupivacaine

Intervention Type DRUG

The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.

Fentanyl

Intervention Type DRUG

20 micrograms routinely administered in combination in the spinal anesthetic

2.5 mg Bupivacaine

2.5mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic

Group Type ACTIVE_COMPARATOR

Bupivacaine

Intervention Type DRUG

The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.

Fentanyl

Intervention Type DRUG

20 micrograms routinely administered in combination in the spinal anesthetic

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupivacaine

The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.

Intervention Type DRUG

Fentanyl

20 micrograms routinely administered in combination in the spinal anesthetic

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fentanyl

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA (American Society of Anesthesiologists Physical status) 1-2 parturients at term requesting labor analgesia
* between 37 and 42 weeks gestational age
* maternal age of 18 years or greater

Exclusion Criteria

* Parturients with pre-eclampsia
* History of pregnancy induced hypertension
* Patients in whom a spinal anesthetic is contraindicated (e.g. coagulopathy, local infection) or those in whom a CSE cannot be performed
* Patients with non reassuring fetal heart rate tracings prior to placement of the CSE
Minimum Eligible Age

18 Years

Maximum Eligible Age

48 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

St. Luke's-Roosevelt Hospital Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jonathan Epstein, M.D.

Role: PRINCIPAL_INVESTIGATOR

Mount Sinai Roosevelt Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Roosevelt hospital

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GCO 13-0210

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Epidural Neostigmine for Labor Pain
NCT00779467 COMPLETED PHASE1
Spinal Analgesia in Labour Pain
NCT07332130 NOT_YET_RECRUITING PHASE1